Gossamer Bio, Inc. (Nasdaq: GOSS), today announced that two abstracts supporting GB002, the Company’s inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension (PAH), have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2019 being held November 16- 18 in Philadelphia, Pennsylvania.
November 11, 2019
· 2 min read